Alixer Nexgen Therapeutics is a next-generation biopharmaceutical organization focused on discovering and developing innovative therapies addressing significant unmet medical needs.
Built on a foundation of scientific rigor, collaborative innovation, and translational research, the organization integrates advanced biology, technology-enabled development models, and strategic global partnerships to accelerate therapeutic advancement.
As a wholly owned subsidiary of Alkem Laboratories Ltd, Alixer combines the strength of an established pharmaceutical legacy with the agility of a modern innovation-focused biotech ecosystem.
Pioneering first-in-class and best-in-class therapies
Strong partnerships with leading academic institutions and innovators
Translational research powered by advanced technologies
Developing therapies for patients worldwide
Addressing unmet needs with precision and purpose
The organization collaborates with leading academic institutions, translational research groups, biotechnology innovators, and clinical experts to identify novel therapeutic opportunities and support scalable therapeutic development. By combining scientific expertise, biomarker-guided strategies, AI-enabled insights, and regulatory-aligned development frameworks, Alixer aims to improve development efficiency.
Founding Director, Wyss Institute, Harvard University
Dr. Ingber is a renowned physician-scientist, bioengineer, and a professor at Harvard Medical School and Harvard SEAS, known for pioneering innovations in mechanobiology, tissue engineering, organ-on-a-chip technology and NAMs.
Managing Director, RTK Group and Faculty at Harvard Medical School
Dr. Muni is a physician, biotech executive, and investor with more than 25 years of experience spanning healthcare, pharmaceuticals, biotechnology, and the FDA. He mentors’ innovators at Harvard’s Wyss Institute for Biologically Inspired Engineering.
Professor and Deputy Chair, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
Dr. Kopetz is an internationally recognized leader in colorectal cancer research. His work focuses on translational oncology, precision medicine, and the development of targeted therapies for metastatic colorectal cancer, helping advance both clinical practice and FDA-approved treatment strategies.
Director, Colorectal Surgery Professor, Augusta University
Prof. Gearhart is a nationally recognized colorectal surgeon and surgical oncologist. Her clinical and research interests focus on colorectal cancer, hereditary cancer syndromes, and advanced surgical treatments, with significant contributions to improving outcomes for patients with gastrointestinal malignancies.
Chairman Medical Oncology, Max Healthcare and Former Head of Medical Oncology, AIIMS, New Delhi
Dr. Sharma carries over three decades of experience in cancer care and research. He has made significant contributions to clinical oncology, hematopoietic stem cell transplantation, and the development of evidence-based therapies for gastrointestinal, breast, lung, and hematological cancers.
Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University
Prof. George is a globally renowned geneticist and pioneer in genomics, synthetic biology, and genome engineering at Harvard Medical School and MIT. His groundbreaking contributions to next-generation sequencing, CRISPR-based genome editing, personalized medicine, and synthetic biology have transformed modern biotechnology and advanced therapeutic innovation worldwide.
Whole Time Director
Mrs. Madhurima Singh is an Executive Director on the Board of Alkem Laboratories. She has been actively involved across multiple business functions and contributed to several strategic initiatives over the years.
Her work spans areas including human resources, legal and compliance, supply chain, corporate communication, CSR, and indirect procurement. She has also played an important role in strengthening the company’s semi-chronic business and supporting the growth of active pharmaceutical ingredients (API) business.
Mrs. Singh has been associated with initiatives focused on people practices, brand and reputation building, R&D, adoption of new-age technologies, sustainability, and social impact. Her areas of expertise include pharmaceutical marketing, strategy, financial oversight, human resources, governance and compliance, manufacturing operations, and supply chain management.
Mrs. Singh was recognised among Business Today’s Most Powerful Women in Business in 2025.
Board Director – Alkem MedTech
Mr. Srinivas Singh has been associated with Alkem since 2012 and joined the Board in 2022. He has been involved across areas including R&D, portfolio management, product launches, and strategic initiatives for global markets.
Over the years, he has contributed to strengthening the company’s product pipeline, supporting new product introductions, and driving initiatives related to cost optimisation, alternate sourcing, and risk assessment. He has also been closely associated with medical device segment and projects focused on sales digitalisation, and operational efficiency across functions.
He continues to contribute across strategic and operational priorities, with a focus on strengthening innovation capabilities, improving agility, and supporting long-term business readiness. Beyond business initiatives, Mr. Singh supports the company’s CSR efforts, contributing to programmes focused on community welfare and social development. He holds a Bachelor of Science degree.
Mr. Srinivas Singh has been associated with Alkem since 2012 and joined the Board in 2022. He has been involved across areas including R&D, portfolio management, product launches, and strategic initiatives for global markets.
Over the years, he has contributed to strengthening the company’s product pipeline, supporting new product introductions, and driving initiatives related to cost optimisation, alternate sourcing, and risk assessment. He has also been closely associated with medical device segment and projects focused on sales digitalisation, and operational efficiency across functions.
He continues to contribute across strategic and operational priorities, with a focus on strengthening innovation capabilities, improving agility, and supporting long-term business readiness. Beyond business initiatives, Mr. Singh supports the company’s CSR efforts, contributing to programmes focused on community welfare and social development. He holds a Bachelor of Science degree.
Whole Time Director
Dr Akhilesh Sharma is an M.D. from Mumbai and Fellow of Royal Liverpool hospital society-U.K, with advanced training in Clinical Research from Berkley Extension, California State University, USA and PV from Luton Medical Centre, UK.
A visionary pharmaceutical executive with 30+ years’ experience in development of NCEs, biologics, cell & gene therapies, and complex generics. His expertise spans AI – driven drug development, translational medicine, biomarker development, Clinical R&D, market access, regulatory strategy, executive leadership, BD & global partnership across multinational pharmaceutical companies, based out of US & India.
He has a proven track record in building and leading high-performance global functions at Alkem, Dr. Reddy’s, Glenmark, Rhône-Poulenc Rorer (Aventis), Carter Wallace, Cell Therapeutics Inc. and as an entrepreneur with GeneXY (biomarker development organization in Philadelphia, jointly with Wistar institute, Pennsylvania University campus), RYTUS Therapeutics.
He combines scientific depth with commercial acuity to forge academic co-development partnerships with Harvard, Johns Hopkins, U. Chicago, Texas Tech University-Medical Sciences, Memorial Sloan Kettering, Miami University, NIH, Karolinska, IIT-Bombay/ Kanpur, IISc-Bangalore; and others, at the same time unlocks successful regulatory pathways with agencies worldwide such as US FDA, EMA, MHRA, TGA, MCC, DCGI, and translate innovation into measurable business value. He has created more than $6500M+ innovation driven patented product portfolio during his entire tenure.
He is the Founding Director of Alixer NexGen Therapeutics Ltd., Alkem’s independent wholly owned Proprietary Subsidiary; and currently serves as President & Chief Medical Officer of Alkem Laboratories Ltd. He also serves on Board of Directors of Haystacks Analytics Pvt Ltd
In addition, he is an advisor to special projects at Harvard-Wyss, visiting faculty at Johns Hopkins University, Harvard-Wyss, (USA), Karolinska, Europe, IIT’s (premium technology institutes-India) and others. Been on panel of Drug Development, Clinical Research and Drug Safety at various national and international forums including at USFDA workshops and an invited faculty at leading international conferences & institutes.
He has to his credit more than 71 scientific & research publications, 58 patents and holds membership of International Pharmaceutical Society, American Academy of Dermatology, American Diabetes Association, European Society of Respiratory Medicine. He has been honored with a Lifetime Achievement Award in recognition of his contributions to biotechnology innovation and the development of cutting-edge therapies for patients.
Managing Director – Alkem Laboratories Ltd
Mr. Sandeep Singh joined Alkem’s Board in 2013 and currently serves as the Managing Director of the company. He leads the domestic and international business operations and has been actively involved in expanding the company’s presence across geographies and therapies.
Over the years, he has played an important role in scaling the company’s commercial operations, strengthening market reach, and driving execution across businesses. He also oversees Alkem’s emerging growth areas, including biosimilars and Medtech business, which are expected to contribute to the company’s next phase of growth.
His areas of expertise include business strategy, pharmaceutical marketing, financial oversight, governance and compliance, risk management, manufacturing operations, supply chain, and strategic investments.
He also serves on the boards of several group companies, including biotech arm Enzene Biosciences Limited and Alkem Medtech Private Limited.
Mr. Singh was recognised with the Emerging Pharma Leader of the Year award in 2016 and was featured in the ET & Spencer Stuart 40 Under 40 list in 2021.
Board Director – Alkem MedTech
Mr. Aniruddha Singh has been associated with Alkem since 2022. He brings a strategic lens to the company’s evolving business priorities, with a keen interest in innovation, emerging healthcare opportunities, and new models of growth.
His focus on enhancing capabilities is reflected in his active involvement in R&D and innovation, the company’s foray into medical devices, and the assessment of new business and acquisition opportunities. He also contributes to strengthening collaboration and efficiency across Alkem’s global businesses and to initiatives focused on developing young talent.
Mr. Singh holds a Master’s degree in Management from London Business School and a Bachelor’s degree in Management Studies, with a major in Finance, from H.R. College of Commerce and Economics, Mumbai.
Whole Time Director
Dr Akhilesh Sharma is an M.D. from Mumbai and Fellow of Royal Liverpool hospital society-U.K, with advanced training in Clinical Research from Berkley Extension, California State University, USA and PV from Luton Medical Centre, UK.
A visionary pharmaceutical executive with 30+ years’ experience in development of NCEs, biologics, cell & gene therapies, and complex generics. His expertise spans AI – driven drug development, translational medicine, biomarker development, Clinical R&D, market access, regulatory strategy, executive leadership, BD & global partnership across multinational pharmaceutical companies, based out of US & India.
He has a proven track record in building and leading high-performance global functions at Alkem, Dr. Reddy’s, Glenmark, Rhône-Poulenc Rorer (Aventis), Carter Wallace, Cell Therapeutics Inc. and as an entrepreneur with GeneXY (biomarker development organization in Philadelphia, jointly with Wistar institute, Pennsylvania University campus), RYTUS Therapeutics.
He combines scientific depth with commercial acuity to forge academic co-development partnerships with Harvard, Johns Hopkins, U. Chicago, Texas Tech University-Medical Sciences, Memorial Sloan Kettering, Miami University, NIH, Karolinska, IIT-Bombay/ Kanpur, IISc-Bangalore; and others, at the same time unlocks successful regulatory pathways with agencies worldwide such as US FDA, EMA, MHRA, TGA, MCC, DCGI, and translate innovation into measurable business value. He has created more than $6500M+ innovation driven patented product portfolio during his entire tenure.
He is the Founding Director of Alixer NexGen Therapeutics Ltd., Alkem’s independent wholly owned Proprietary Subsidiary; and currently serves as President & Chief Medical Officer of Alkem Laboratories Ltd. He also serves on Board of Directors of Haystacks Analytics Pvt Ltd
In addition, he is an advisor to special projects at Harvard-Wyss, visiting faculty at Johns Hopkins University, Harvard-Wyss, (USA), Karolinska, Europe, IIT’s (premium technology institutes-India) and others. Been on panel of Drug Development, Clinical Research and Drug Safety at various national and international forums including at USFDA workshops and an invited faculty at leading international conferences & institutes.
He has to his credit more than 71 scientific & research publications, 58 patents and holds membership of International Pharmaceutical Society, American Academy of Dermatology, American Diabetes Association, European Society of Respiratory Medicine. He has been honored with a Lifetime Achievement Award in recognition of his contributions to biotechnology innovation and the development of cutting-edge therapies for patients.
Vice President & Program Director
Dr Sangle brings extensive expertise in translational biology and strategic drug discovery with a proven track record of leading multiple INDs across the US and India. With close to two decades in biopharma/biotech, including experience at Amneal Pharmaceuticals, Kashiv Biosciences, Wockhardt Ltd, Novartis, and Lupin, Dr Sangle has become a leader in leveraging cutting-edge technologies for drug discovery. He excels at transforming complex scientific concepts into actionable processes, fostering cross-functional collaboration, and has expertise in leading several novel programs in NCEs, biologics, and peptides. His blend of pharmacology expertise and ability to build strategic collaborations makes him a key innovator, continually pushing boundaries in drug discovery and development. His experience spans target identification to early clinical development, alongside strong capabilities in regulatory strategy, due diligence, and portfolio expansion.
He holds a Master’s in Pharmacy (Pharmacology) from Dr. MGR Medical University, Chennai, India; a Ph.D. in Physiology & Pathophysiology from the Faculty of Medicine, University of Manitoba, Winnipeg, Canada; and a Banting & Best Diabetes Centre-sponsored postdoctoral fellowship in GLP-1 research from the University of Toronto.
Whole time Director
Director
Whole Time Director
Managing Director – Alkem Laboratories Ltd
Board Director – Alkem Medtech
Whole Time Director
Vice President & Program Director
In addition to strong leadership, the organization is building a multidisciplinary team encompassing in‑vitro and in‑vivo pharmacology, toxicology, cell and molecular biology, therapeutic and medical leadership, global regulatory strategy, intellectual property, business development, and clinical development — collectively enabling a fully integrated, end‑to‑end drug discovery and development engine that seamlessly translates scientific innovation into clinically and commercially viable therapies.
Whole Time Director
Vice President & Program Director
Founding director, Wyss Institute, Harvard University
Dr. Ingber is a renowned physician-scientist, bioengineer, and a professor at Harvard Medical School and Harvard SEAS, known for pioneering innovations in mechanobiology, tissue engineering, organ-on-a-chip technology and NAMs.
Managing Director, RTK Group and Faculty at Harvard Medical School
Dr. Muni is a physician, biotech executive, and investor with more than 25 years of experience spanning healthcare, pharmaceuticals, biotechnology, and the FDA. He mentors’ innovators at Harvard’s Wyss Institute for Biologically Inspired Engineering.
Professor and Deputy Chair, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
Dr. Kopetz is an internationally recognized leader in colorectal cancer research. His work focuses on translational oncology, precision medicine, and the development of targeted therapies for metastatic colorectal cancer, helping advance both clinical practice and FDA-approved treatment strategies.
Director, Colorectal Surgery Professor, Augusta University
Prof. Gearhart is a nationally recognized colorectal surgeon and surgical oncologist. Her clinical and research interests focus on colorectal cancer, hereditary cancer syndromes, and advanced surgical treatments, with significant contributions to improving outcomes for patients with gastrointestinal malignancies.
Chairman Medical Oncology, Max Healthcare and Former Head of Medical Oncology, AIIMS, New Delhi
Dr. Sharma carries over three decades of experience in cancer care and research. He has made significant contributions to clinical oncology, hematopoietic stem cell transplantation, and the development of evidence-based therapies for gastrointestinal, breast, lung, and hematological cancers.
Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University
Prof. George is a globally renowned geneticist and pioneer in genomics, synthetic biology, and genome engineering at Harvard Medical School and MIT. His groundbreaking contributions to next-generation sequencing, CRISPR-based genome editing, personalized medicine, and synthetic biology have transformed modern biotechnology and advanced therapeutic innovation worldwide.
Whole Time Director
Dr Akhilesh Sharma is an M.D. from Mumbai and Fellow of Royal Liverpool hospital society-U.K, with advanced training in Clinical Research from Berkley Extension, California State University, USA and PV from Luton Medical Centre, UK.
A visionary pharmaceutical executive with 30+ years’ experience in development of NCEs, biologics, cell & gene therapies, and complex generics. His expertise spans AI – driven drug development, translational medicine, biomarker development, Clinical R&D, market access, regulatory strategy, executive leadership, BD & global partnership across multinational pharmaceutical companies, based out of US & India.
He has a proven track record in building and leading high-performance global functions at Alkem, Dr. Reddy’s, Glenmark, Rhône-Poulenc Rorer (Aventis), Carter Wallace, Cell Therapeutics Inc. and as an entrepreneur with GeneXY (biomarker development organization in Philadelphia, jointly with Wistar institute, Pennsylvania University campus), RYTUS Therapeutics.
He combines scientific depth with commercial acuity to forge academic co-development partnerships with Harvard, Johns Hopkins, U. Chicago, Texas Tech University-Medical Sciences, Memorial Sloan Kettering, Miami University, NIH, Karolinska, IIT-Bombay/ Kanpur, IISc-Bangalore; and others, at the same time unlocks successful regulatory pathways with agencies worldwide such as US FDA, EMA, MHRA, TGA, MCC, DCGI, and translate innovation into measurable business value. He has created more than $6500M+ innovation driven patented product portfolio during his entire tenure.
He is the Founding Director of Alixer NexGen Therapeutics Ltd., Alkem’s independent wholly owned Proprietary Subsidiary; and currently serves as President & Chief Medical Officer of Alkem Laboratories Ltd. He also serves on Board of Directors of Haystacks Analytics Pvt Ltd
In addition, he is an advisor to special projects at Harvard-Wyss, visiting faculty at Johns Hopkins University, Harvard-Wyss, (USA), Karolinska, Europe, IIT’s (premium technology institutes-India) and others. Been on panel of Drug Development, Clinical Research and Drug Safety at various national and international forums including at USFDA workshops and an invited faculty at leading international conferences & institutes.
He has to his credit more than 71 scientific & research publications, 58 patents and holds membership of International Pharmaceutical Society, American Academy of Dermatology, American Diabetes Association, European Society of Respiratory Medicine. He has been honored with a Lifetime Achievement Award in recognition of his contributions to biotechnology innovation and the development of cutting-edge therapies for patients.
Vice President & Program Director
Dr Sangle brings extensive expertise in translational biology and strategic drug discovery with a proven track record of leading multiple INDs across the US and India. With close to two decades in biopharma/biotech, including experience at Amneal Pharmaceuticals, Kashiv Biosciences, Wockhardt Ltd, Novartis, and Lupin, Dr Sangle has become a leader in leveraging cutting-edge technologies for drug discovery. He excels at transforming complex scientific concepts into actionable processes, fostering cross-functional collaboration, and has expertise in leading several novel programs in NCEs, biologics, and peptides. His blend of pharmacology expertise and ability to build strategic collaborations makes him a key innovator, continually pushing boundaries in drug discovery and development. His experience spans target identification to early clinical development, alongside strong capabilities in regulatory strategy, due diligence, and portfolio expansion.
He holds a Master’s in Pharmacy (Pharmacology) from Dr. MGR Medical University, Chennai, India; a Ph.D. in Physiology & Pathophysiology from the Faculty of Medicine, University of Manitoba, Winnipeg, Canada; and a Banting & Best Diabetes Centre-sponsored postdoctoral fellowship in GLP-1 research from the University of Toronto.
Whole Time Director
Director
Whole Time Director
MD – Alkem Laboratories Ltd
Board Director – Alkem MedTech
Alkem upholds the highest standards of compliance and governance while creating long-term societal impact through research and innovation. Through its CSR initiative, the Company established Alkem’s Center for Advanced Research and Development in Regenerative Medicine and Cell Therapies in partnership with IIT Bombay, advancing scientific talent, healthcare innovation, and sustainable solutions that contribute to both social well-being and scientific progress.
Alixer Nexgen is committed to accelerating scientific innovation through collaboration, translational excellence, and next-generation therapeutic development.
